Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2022-01-27 Major Shareholding Noti…
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2022-01-27 English
SC 13G
Major Shareholding Notification
2022-01-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-24 English
FORM 3 SUBMISSION
Director's Dealing
2022-01-24 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 18, 2022, reporting changes in the company's board of directors and appointments to the Audit Committee. It details the appointment of a new director, Paul Hoelscher, and the resignation and non-re-election of other directors. The content focuses exclusively on board and management changes without financial data or other report types. Therefore, it fits the category of Board/Management Information (MANG). The document length and detail confirm it is not a brief announcement but a substantive filing about management changes.
2022-01-24 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the departure of a director or officer (Wendy Johnson) and related agreements such as severance and consulting arrangements. This matches the description of announcements about changes in the company's board of directors or senior management. The relevant filing category is 'Board/Management Information' (MANG). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about management changes.
2021-12-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.